Skip to main content

Oncology Central is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • News
  • Events coverage
  • Features
    • Opinion
    • Journal articles
    • Events calendar
    • Spotlights
    • In Focus

    Follow us on social media

  • Our Journals
  • Topic
    • Prevention, detection and screening
      • Biomarkers
      • Diagnostics
      • Epidemiology
      • Genetics & genomics
      • Prevention & screening
    • Bench to bedside
      • Cancer biology
      • Clinical trials
      • Drug approvals
      • Drug development
      • Emerging technologies
      • Industry & business
      • Preclinical research
    • Treatments
      • Chemotherapy
      • Immuno-oncology
      • Personalized & precision medicine
      • Radiology
      • Surgery
      • Targeted therapies
    • Supportive oncology
      • Palliative care
      • Patient perspectives
      • Quality of life
      • Survivorship
      • Virtual healthcare

    Follow us on social media

  • Disease specialty
    • Breast
    • Colorectal
    • Endocrine
    • Gastrointestinal
    • Genitourinary
    • Gynecologic
    • Head & neck
    • Hematologic
    • Hepatic
    • Lung
    • Neurologic
    • Pancreatic
    • Prostate
    • Rare tumors
    • Renal
    • Skin

    Follow us on social media

  • Multimedia
    • Videos
    • Podcasts
    • Infographics
    • Webinars
    • Downloadable eBooks

    Follow us on social media

  • Register
[COFFEE CHAT] The emotional and psychological impact of hepatocellular carcinoma on patients, families and caregivers WATCH NOW

Melanoma Management

Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis.

View more

Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing.

The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice.

  • About
  • Accessibility
  • Advertising & Sponsorship
  • Contact Us
  • Editorial Policies
  • Expert Panel
  • Journals
  • Permissions and content ownership policy
  • Press release policy
  • Whitelist emails

Contact

Contact Us

Office info

Oncology Central is powered by Taylor & Francis Group

Oncology Central, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Oncology Central